2106 related articles for article (PubMed ID: 16854944)
1. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease.
Kadir A; Almkvist O; Forsberg A; Wall A; Engler H; Långström B; Nordberg A
Neurobiol Aging; 2012 Jan; 33(1):198.e1-14. PubMed ID: 20688420
[TBL] [Abstract][Full Text] [Related]
3. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
5. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
[TBL] [Abstract][Full Text] [Related]
6. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study.
Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; Fox N; Kennedy A; Rossor M; Brooks DJ
Neurology; 2007 Feb; 68(7):501-8. PubMed ID: 17065593
[TBL] [Abstract][Full Text] [Related]
7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
8. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
9. Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case.
Almkvist O; Kadir A; Nordberg A
Neurocase; 2015; 21(6):738-47. PubMed ID: 25494540
[TBL] [Abstract][Full Text] [Related]
10. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
[TBL] [Abstract][Full Text] [Related]
12. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
13. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
[TBL] [Abstract][Full Text] [Related]
14. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
15. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
[TBL] [Abstract][Full Text] [Related]
16. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
17. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
18. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
Scheinin NM; Aalto S; Koikkalainen J; Lötjönen J; Karrasch M; Kemppainen N; Viitanen M; Någren K; Helin S; Scheinin M; Rinne JO
Neurology; 2009 Oct; 73(15):1186-92. PubMed ID: 19726751
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
Ziolko SK; Weissfeld LA; Klunk WE; Mathis CA; Hoge JA; Lopresti BJ; DeKosky ST; Price JC
Neuroimage; 2006 Oct; 33(1):94-102. PubMed ID: 16905334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
